Patients with advanced renal cell carcinoma (RCC) treated with single-agent, oral sunitinib malate (Sutent) reported experiencing significantly lower severity of symptoms like bone pain and breathlessness, among others, than patients treated with interferon-alfa. More>>

The advisory committee to the UK’s National Health Service (NHS) has recommended that the NHS not pay for four new agents proven effective in metastatic renal cell carcinoma. The four drugs are bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent), and temsirolimus (Torisel). More>>

Wyeth Pharmaceuticals recently announced the initiation of the INTORACT (INvestigation of TORisel and Avastin Combination Therapy) study, a worldwide randomized, open-label, phase IIIB study comparing temsirolimus (Torisel) plus bevacizumab (Avastin) vs bevacizumab plus interferon-alfa for first-line treatment of patients with advanced renal cell carcinoma (RCC). Wyeth Research is conducting the INTORACT study with the support and assistance of Roche and Genentech More>>

A multicenter study has found that the experimental targeted therapy everolimus (Cetican, RAD001) delays cancer progression in patients with metastatic kidney cancer that has progressed despite treatment with other targeted therapies. Lead author Robert J. Motzer, md, attending physician at Memorial Sloan-­Kettering Cancer Center, presented the results at the ASCO meeting (abstract LBA5026). More>>

NEW YORK—Antigenics Inc.’s personalized cancer vaccine Oncophage (vitespen) has received its first government approval. More>>

Drs. Rini and Bukowski do an excellent job of updating and commenting on the rapidly evolving field of therapy for metastatic renal cell carcinoma (RCC). More>>

JENKINTOWN, Pa. -- Temsirolimus (Torisel) and the combination of bevacizumab (Avastin) plus interferon are now first-line treatment options for relapsed or unresectable stage IV kidney cancer. More>>

Wyeth Pharmaceuticals recently announced that the US Food and Drug Administration (FDA) has approved temsirolimus (Torisel) for patients with advanced renal cell carcinoma (RCC). More>>

Endocare, Inc, a medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced that six studies and papers demonstrating the effectiveness of cryoablation for treating renal cancer were published in a supplement to the July 2006 issue of Urology. More>>

PRAGUE -- For metastatic kidney cancer, neoadjuvant targeted therapy with Avastin (bevacizumab) and Tarceva (erlotinib) is apparently safe and may prolong progression-free survival, researchers said here. More>>